Key terms
About FENC
Fennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development of sodium thiosulfate for the prevention of ototoxicity from cisplatin in pediatric cancer patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest FENC news
Apr 04
6:26am ET
Buy Rating Reaffirmed for Fennec Pharmaceuticals Following Strategic European Licensing Deal and Strong Financial Outlook
Apr 04
6:11am ET
Fennec price target raised to $18 from $17 at H.C. Wainwright
Apr 01
2:37pm ET
Fennec Pharmaceuticals Reports Strong 2023 Growth
Mar 29
7:35am ET
Fennec Pharmaceuticals: A Strong Buy on PEDMARK’s Success and Expansion Potential
Mar 27
11:25am ET
Fennec participates in a conference call with Craig-Hallum
Mar 27
4:55am ET
Fennec participates in a conference call with Craig-Hallum
Mar 22
1:50pm ET
Fennec participates in a conference call with Craig-Hallum
Mar 22
9:38am ET
Fennec price target raised to $20 from $18 at Craig-Hallum
Mar 21
8:45pm ET
Buy Rating for Fennec Pharmaceuticals Amidst Strong Pedmark Sales and Market Expansion Potential
Mar 21
7:37pm ET
Fennec Pharmaceuticals Files SEC 8-K Report
Mar 21
6:37am ET
Fennec Pharmaceuticals’ Soaring Sales and New Deal
Mar 21
6:03am ET
Fennec reports Q4 EPS (10c), consensus (2c)
Mar 18
3:05pm ET
Fennec price target raised to $18 from $17 at Craig-Hallum
Mar 18
12:35pm ET
Capital One Financial Sticks to Their Buy Rating for Fennec Pharmaceuticals (FENC)
Mar 17
9:37pm ET
Fennec Pharmaceuticals Strikes Major European Deal
Feb 29
12:25pm ET
Buy Rating for Fennec Pharmaceuticals Amid Strong Pedmark Sales and Market Expansion Potential
Feb 29
9:25am ET
Fennec Pharmaceuticals (FENC) Gets a Buy from Craig-Hallum
Feb 29
7:16am ET
Fennec sees FY23 revenue $20.7M-$21.2M, consensus $19.57M
Feb 29
7:16am ET
Fennec sees Q4 revenue $9.2M-$9.7M, consensus $8.06M
Feb 01
9:10am ET
Analysts Offer Insights on Healthcare Companies: Fennec Pharmaceuticals (FENC) and Societal CDMO (SCTL)
No recent press releases are available for FENC
FENC Financials
Key terms
Ad Feedback
FENC Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
FENC Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range